

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Patent Application of

Douglas D. Ross et al.

Application No.: 09/961,086

Filing Date: September 21, 2001

Title: BREAST CANCER RESISTANCE PROTEIN (BCRP) AND THE DNA WHICH ENCODES IT



Group Art Unit: 1642

Examiner: SUSAN NMN UNGAR

Confirmation No.: 6592

**FOURTH
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a **FOURTH** Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By

A handwritten signature in black ink, appearing to read "Malcolm K. McGowan".

Malcolm K. McGowan, Ph.D.
Registration No. 39,300

Date: September 3, 2004


(8/04)

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date September 3, 2004

By: 
Malcolm K. McGowan, Ph.D.
Registration No. 39,300


P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

028754-039

NON-PROVISIONAL
UTILITY PATENT APPLICATION
TRANSMITTAL - 37 CFR 1.53(b)

☐ Duplicate
(check, if applicable)

Assistant Commissioner for Patents
BOX PATENT APPLICATION
Washington, DC 20231



Attorney Docket No. 10312-7 (053836-5001)

First Named Inventor: Ross

Express Mail Label No. EL719362045US

Total Pages of Transmittal Form: 2

Transmitted herewith for filing is the non-provisional utility patent application entitled:

**BREAST CANCER RESISTANCE PROTEIN (BCRP) AND THE DNA WHICH
ENCODES IT**

which is:

an ☐ Original; or

a ☐ Continuation, ☒ Divisional, or ☐ Continuation-in-part (CIP)

of prior Application No. 09/245,808 filed FEBRUARY 5, 1999.

Anticipated Group/Art Unit: _____ or Class _____, Subclass _____.

☐ This non-provisional patent application is based on Provisional Patent Application No. _____, filed _____.

Enclosed are:

- ☒ Specification (including Abstract) and claims: 53 pages.
- ☐ Application Data Sheet.
- ☐ Newly executed/unexecuted Declaration (original/copy).
- ☒ Copy of Declaration from prior application.
- ☐ Separate Power of Attorney (including 37 CFR 3.73(b) statement, if applicable).
- ☒ sheets of drawings (formal) plus one copy.
- ☐ Microfiche computer program (Appendix).
- ☒ Nucleotide and/or Amino Acid Sequence Submission, including:
 - ☒ Computer readable copy
 - ☒ Paper Copy
 - ☒ Verified

Statement.

- ☐ Under PTO-1595 Cover Sheet, an assignment of the invention
- ☒ Name of Assignee: University of Maryland Baltimore
- ☐ Certified copy(ies) of _____ Application No(s). _____ filed _____ is/are filed:
 - ☐ herewith
 - or
 - ☐ in prior application &@.
- ☒ Applicant(s), by its/their undersigned attorney, claim(s) Small Entity Status under 37 C.F.R. §1.27 as ☐ an Independent Inventor, or ☐ a Small Business Concern, or ☒ a Non-Profit Organization.
- ☒ Preliminary Amendment.
- ☒ Information Disclosure Statement and PTO-1449.
- ☐ Request for Nonpublication of Application Under 35 U.S.C. §122(b)
- ☐ Other:

The filing fee is calculated as follows:

			SMALL ENTITY			LARGE ENTITY	
CLAIMS	NO. FILED	NO. EXTRA	BASIC FEE: \$355			BASIC FEE: \$710	
Total	7-20 =	0	X9	\$	OR	X18	\$
Independent	1- 3=	0	X40	\$	OR	X80	\$
[] Multiple Dependent Claims Present			\$135	\$	OR	\$270	\$
			TOTAL	\$ 355.00	OR	TOTAL	\$

[] The Commissioner is not authorized to charge the filing fee at this time as we elect to defer payment of the entire filing fee until receipt of a Notice to File Missing Parts.

[X] A check in the amount of \$355.00 to cover the filing fee is enclosed.

[X] The Commissioner is hereby authorized to charge and/or credit **Deposit Account No. 50-0310 (Billing No. 503836-5001)** as noted below. A duplicate copy of this sheet is enclosed.

[X] Any overpayments or deficiencies in the above-calculated fee.

[] Filing fee in the amount of \$_____ as calculated above.

[X] Any additional fees required under 37 C.F.R. § 1.16 and § 1.17.

[X] In the event that a Petition for Extension of Time is required during the prosecution of this application, but not submitted, please charge any extension fee under 37 C.F.R. § 1.136(a) to our Deposit Account noted above.

CORRESPONDENCE ADDRESS:

ROSS, et al.

By:

Kathryn Doyle
KATHRYN DOYLE, Ph.D., J.D.
Registration No. 36,317
MORGAN, LEWIS & BOCKIUS, LLP
1701 Market Street
Philadelphia, PA 19103-2921
Telephone: (215) 963-5000
Direct Dial: (215) 963-4723
Facsimile: (215) 963-5299
E-Mail: kdoyle@morganlewis.com
Attorney for Applicants


SEPTEMBER 21, 2001
(Date)

[X] Customer Number or Bar Code Label: 028977

KD/kck
Enclosures

COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Patent Application of Ross		: Group Art Unit Not Yet Assigned
Appln. No.:	Filed Herewith		: Examiner: Not Yet Assigned
Filed:	Herewith		:
For:	BREAST CANCER RESISTANCE PROTEIN (BCRP) AND THE DNA ENCODES IT		: Attorney Docket : No. 53836-5001

INFORMATION DISCLOSURE STATEMENT

It is requested that the enclosed reference(s) listed on the attached Information Disclosure Citation Form PTO-1449 be considered by the Patent Examiner in connection with the above-identified application and be made of record therein.


Independent consideration and acknowledgment of the enclosed reference(s) are respectfully requested.

Respectfully submitted,

ROSS, *et al.*


SEPTEMBER 21, 2001
(Date)

By:


KATHRYN DOYLE, Ph.D, J.D.
Registration No. 36,317
MORGAN, LEWIS & BOCKIUS, LLP
1701 Market Street
Philadelphia, PA 19103-2921
Telephone: (215) 963-5000
Direct Dial: (215) 963-4723
Facsimile: (215) 963-5299
E-Mail: kdoyle@morganlewis.com
Attorney for Applicants

KD/kck
Enclosure

COPY

FORM PTO 1449 INFORMATION DISCLOSURE STATEMENT 	ATTY. DOCKET NO. 10460-7 (53836-5001)	APPLICATION NO. Not Yet Assigned
	APPLICANT(S) Ross et al.	
	FILING DATE Herewith	GROUP 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1						Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	1	Amplification of 4q21-q22 and the MXR Gene in Independently Derived Mitoxantrone-Resistant Cell lines, Turid Knusten, V. Konei Rao, Thomas Ried, Lyn Mickley, Eramus Schneider, Keisuke Miyake, B. Michael Ghadimi, Hesed Padilla-Nash, Svetlana Pack, Lee Greeneberger, Kenneth Cowan, Michael Dean, Tito Fojo, and Susan Bates, Genes, Chromosomes and Cancer, Vol. 27 pp. 110-116.
AS	1	
AT	1	
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE
(REV. 8-83) PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.:

10460-7 (53836-5001)

APPLICATION NO.:

Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

(Form PTO-1449 Modified 5/95)
(Use several sheets if necessary)

APPLICANT.:

D. Ross et al.

028754-039

FILING DATE:

Herewith

GROUP ART UNIT:

1642

U.S. PATENT DOCUMENTS

EX. INIT	DOCU - MENT	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS


EX. INIT	DOCU - MENT	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
		WO 98/55614	December 1998	International			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 14 INFORMATION DISCLOSURE STATEMENT 	ATTY. DOCKET NO. 10460-7 (53836-5001)	APPLICATION NO. Not Yet Assigned
	APPLICANT(S) 028754-039	
	FILING DATE Herewith	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1					
	AB1					
	AC1					
	AD1					
	AE1					
	AF1					
	AG1					
	AH1					
	AI1					
	AJ1					
	AK1					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1					Yes No
	AM1					Yes No
	AN1					Yes No
	AO1					Yes No
	AP1					Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	1	Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell Lines. Douglas D. Ross, Weidong Yang, Lynne V. Abruzzo, William S. Dalton, Erasmus Schneider, Hermann Lage, Munfred Dietel, Lee Greenberger, Susan P.C. Cole, L. Austin Doyle. JNCI, Vol. 91, No. 5, 1/28/99, pp. 1-11.
AS	1	Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the Expressed Sequence Tags database. Rando Allikmets, Bernard Gerrard, Amy Hutchinson and Michael Dean, Human Molecular Genetics, 1996, Vol. 5, No.1, pp. 1649-1655.
AT	1	Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line. S.P.C. Cole, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M.V. Duncan, R.G. Deeley, Vol. 258, December 4, 1992, pp. 1650-1654.
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

FORM PTO 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	10460-7 (53836-5001)	Not Yet Assigned
	APPLICANT(S)	
	028754-039	
FILING DATE		GROUP
Herewith		1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1					
	AB1					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AC1					Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AD	1	Reduced Intracellular Drug Accumulation in the Absence of P-Glycoprotein (mdr1) Overexpression in Mitoxantrone-resistant Human MCF-7 Breast Cancer Cells, Masayuki Nakagawa, Erasmus Schneider, Katharine H. Dixon, Julie Horton, Kristin Kelly, Charles Morrow, Kenneth H. Cowan, Cancer Research, Vol. 52, 6175-6181, November 15, 1992.
AE	1	Cross-Resistance to Camptothecin Analogues in a Mitoxantrone-resistant Human Breast Carcinoma Cell Line Is Not Due to DNA Topoisomerase I Alterations, Chih-Hsin J. Yang, Julie K. Horton, Kenneth H. Cowan and Erasmus Schneider, Cancer Research Vol. 55, pp. 4004-4009, September 15, 1995.
AF	1	Characterization of Adriamycin-resistant Human Breast Cancer Cells Which Display Overexpression of a Novel Resistance-related Membrane Protein, Yi-Nan Chen, Lyn A. Mickley, Arnold M. Schwartz, Edward M. Action, Jaulang Hwang, and Antonio T. Fojo, The Journal of Biological Chemistry, Vol 265, No 17, pp10073-10080, June 15, 1999.
AG	1	Membrane Vesicle Formation Due Acquired Mitoxantrone Resistance in Human Gastric Carcinoma Cell Line EPG85-257, Manfred Dietel, Hartmut Arps, Hermann Lage and Axel Niendorf, Cancer Research, Vol. 50, 6100-6106, September 15, 1990.
AH	1	Different Mechanisms of Decreased Drug Accumulation in Doxorubicin and mitoxantrone resistant variants of the MCF7 Human Breast Cancer Cell line, C.W. Taylor, W.S. Dalton, P.R. Parrish, M.C. Gleason, W.T. Bellamy, F.H. Thompson, D.J. Roe and J.M. Trent, J. Cancer Vol. 63, pp. 923-929, (1991).
AI	1	Fumitremogin C Reverse Multidrug Resistance in Cells Transfected with the Breast Cancer Resistance Protein, Sridhar K. Radindran, Douglas D. Ross, L. Austin Doyle, Weidong Yang, and Lee M. Greenberger, Cancer Research, Vol. 60, pp. 47-50, January 1, 2000.
AJ	1	Analysis of MRP mRNA in Mitoxantrone-Selected, Multidrug-Resistant Human Tumor Cells, Bernard W. Futscher, Mohammad R. Abbaszadegan, Frederick Domann, and William S. Dalton, Biochemical Pharmacology, Vol. 47, No. 9 pp. 1601-1606, 1994.
AK	1	Cytogenetic and Phenotypic Analysis of a Human Colon Carcinoma Cell Line Resistant To Mitoxantrone, William S. Dalton, Anne E. Cress, David S. Alberts and Jeffery M. Trent, Cancer Research, Vol. 48, 1882-1888, April 1, 1988.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO 1449	ATTY. DOCKET NO 10460-7 (53836-5001)	APPLICATION NO. Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT 	APPLICANT(S) Ross et al. 028754-039	
	FILING DATE Herewith	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1					
	AB1					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AC					Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AD	1	Reduced Drug Accumulation and Multidrug Resistance in Human Breast Cancer Cells without Associated P-Glycoprotein or MPR Overexpression, Jong Seok Lee, Stefania Scala, Yoshihito Matsumoto, Bruce Dickstein, Rob Robey, Zhirong Zhan, Guillermo Altenberg, and Susan E. Bates, Journal of Cellular Biochemistry Vol. 65, pp. 513-526, 1997.
AE	1	Decreased Drug Accumulation in a Mitoxantrone-Resistant Gastric Carcinoma Cell Line in the Absence of P-Glycoprotein, Udo Kellner, Lesley Hutchinson, Andre Seidel, Hermann Lage, Mary K. Danks, Manfred Dietel and Scott H., Kaufmann, Int. J. Cancer Vol. 71, pp. 817-824, 1997.
AF		Reduced Cellular Accumulation of Topotecan: a novel Mechanism of Resistance in a Human Ovarian Cancer Cell Line, J. Ma, M. Maliepaard, K. Nooter, WJ. Loos, H.J. Kolker, J. Verweij, G. Stoter and JHM Schellens, British Journal of Cancer, Vol. 77(10), pp. 1645-1652, 1998.
AG	1	Reversal of a Novel Multidrug Resistance Mechanism in Human Colon Carcinoma Cells By Fumitremorgin C, Sridhar K. Rabindran, Haiyin He, Maya Singh, Eileen Brown, Karen I. Collins, Tami Annable, and Lee M. Greenberger, Cancer Research Vol. 58, pp. 5850-5858, December 15, 1998.
AH	1	Overexpression of the BCRP/MXR/ABCP Gene in a Topotecan-selected Ovarian Tumor Cell Line, Marc Maliepaards, Margot A. Van Gastelen, Laurina A. de Jong, Dick Pluim, Robert C. A. M. van Waardenburg, Marjan C. Ruevekamp-Helmers, Ben G. J. Froot, and Jan H. M. Schellens, Cancer Research Vol. 59, pp 4559-4563, September 15, 1999.
AI	1	Expression of the Novel Mitoxantrone Resistance Associated Gene MXR7 in Colorectal Malignancies, H. Lage, M. Dietel, G. Froschle, and Reymann, International Journal of Clinical Pharmacology and Therapeutics, Vol. 36, No. 1, page 58-60, 1998.
AJ	1	The Mouse Bcrp1/Mxr/Abcp Gene: Amplification and Overexpression in Cell Lines Selected Resistance Topotecan, Mitoxantrone, or Doxorubicin, John D. Allen, Remco F. Brinkhuis, Jan Wijnholds and Alfred H. Schinkel, Cancer Research, 4237-424, September 1, 1999.
AK	1	Multiple Mechanisms Confer Drug Resistance to Mitoxantrone in the Human 8226 Myeloma Cell Line, Lori A. Hazlehurst, Nils F. Foley, Mary C. Gleason-Guzman, Miles P. Hacker, Anne E. Cress, Lee W. Greenberger, Mariska C. De Jong, and William S. Dalton, Cancer Research, Vol. 59, pp. 1-8, March 1, 2000.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	10460-7 (53836-5001)	Not Yet Assigned
	APPLICANT(S)	
	028754-039	
FILING DATE		GROUP
Herewith		1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1					
	AB1					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AC					Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AD	1	Multidrug Resistance-associated Protein Gene Overexpression and Reduced Drug Sensitivity of Topoisomerase II in a Human Breast Carcinoma MCF7 Cell Line Selected for Etoposide Resistance, Erasmus Schneider, Julie K. Horton, Chih-Hsin Yang, Masayuki Nakagawa, and Kenneth H. Cowan, Cancer Research, Vol. 54, pp. 152-158, January 1, 1994.
AE	1	Isolated of Amplified and Overexpressed DNA sequences from Adriamycin-resistant Human Breast Cancer Cells, Craig R. Fairchild, S. Percy Ivy, Chien-Song Kao-Shan, Jacqueline Whang-Peng, Neal Rosen, Mark A. Israel, Peter W. Melera, Kenneth H. Cowan, And Merrill E. Goldsmith, Cancer Research, Vol 47, pp. 5141-5148, October 1, 1987.
AF		Reversion of Multidrug Resistance in the P-glycoprotein-positive Human Pancreatic Cell Line I (EPP85-181RDB) by Introduction of a Hammerhead Ribzyme, P.S. Holm, K.J. Scanlon, and M. Dietel.
AG	1	Novel Mechanisms of Drug Resistance in Leukemia, DD Ross, 2000
AH	1	Cloning of DNA Sequences from the White Locus of D. Melanogaster by a Novel and General Method, Cell, Vol. 25, pp. 693-704, September 1981.
AI	1	Studies on the Mechanism of Fatty Acid Synthesis, E.L. Pugh and Salih J. Wakil, The Journal of Biological Chemistry, Vol. 240, No. 12, December 1965.
AJ	1	DNA Sequence of the White Locus of Drosophila Melanogaster, Devin O'Hare, Christine Murphy, Robert Levis and Gerald M. Rubin, J. Mol.Biol. Vol. 180, pp. 437-455.
AK	1	Camptothecin Resistance: Role of the ATP-binding Cassette (ABC), Mitoxantrone-resistance Half Transporter (MXR), and Potential for Glucuronidation in MXR-expressing Cells, Cancer Research, Vol. 59, pp. 5938-5946, December 1, 1999
AL	1	Cellular Resistance to Actinomycin D in Chinese Hamster Cells in Vitro: Cross Resistance, Radioautographic and Cytogenetic Studies, June L. Biedler and Hansjorg Riehm, Cancer Research, Vol. 30, pp. 1174-1184, April 1970.
AM	1	Isolation of Amplified and Overexpressed DNA Sequences from Adriamycin-Resistant Human Breast Cancer Cells, Craig R. Fairchild, S. Percy Ivy, Chien-Song Kao-Shan, Jacqueline Whang-Peng, Neal Rosen, Mark A. Israel, Peter W. Melera, Kenneth H. Cowan, and Merrill E. Goldsmith, Cancer Research 47, pp. 5141-5148, October 1, 1987.
AN	1	Multidrug Resistance in Mitoxantrone-selected HL-60 Leukemia Cells in the Absence of P-Glycoprotein Overexpression, W. Grzydon Harker, D. Lynn Slade, William S. Dalton, Paul S. Meltzer and Jeffrey M. Trent, Cancer Research, Vol. 49, pp. 4542-4549, August 15, 1989.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO 1449	ATTY. DOCKET NO. 10460-7 (53836-5001)	APPLICATION NO. Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT 	APPLICANT(S) Ross et al. 028754-039	
	FILING DATE Herewith	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1					
	AB1					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AC					Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AD	1	New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening, Philip Skehan, Ritsa Storeng, Dominic Scudiero, Anne Monks, James McMahon, David Vistica, Jonathan T. Warren, Heidi Bokesch, Susan Kenney, Michael R. Boyd, J National Cancer Institute, Vol. 82, No. 13, July 14, 1990
AE	1	Derivation of Specific Antibody-Producing Tissue Culture and Tumor Lines By Cell Fusion, G. Kohler, and C. Milstein, Eur. J. Immunol., Vol 6, pp. 511-519, 1976.
AF		Differential Display and Cloning of Messenger RNAs from Human Breast Cancer versus Mammary Epithelial Cells, Peng Liang, Lidia Averboukh, Khandan Keyomarsi, Ruth Sager, and Auther B. Pardee, Cancer Research, Vol. 52, pp. 6966-6968, December 15, 1992.
AG	1	Reduced Permeability in CHO Cells as a Mechanism of Resistance to Colchicine, Victor Ling and Larry H. Thompson, J. Cell Physiol, Vol. 83, page 103-116.
AH	1	Fusion between Immunoglobuline-secreting and Nonsecreting Myeloma Cell Lines, G. Kohler, and S.C. Howe and C. Milstein, Eur. J. Immunol., Vol. 6, pp. 292-295, 1976.
AI	1	Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction, Peng Liang, and Arthur B. Pardee, Science, Vol. 257, pp. 967-971, August 14, 1992.
AJ	1	Sequence of a cDNA from the Drosophila Melanogaster White Gene, Nucleic Acids Research, Vol. 18, No. 6, pp. 1633, February 20, 1990.
AK	1	Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity, Nature, G. Kohler, C. Milstein, Vol. 256, August 7, 1975.
AL	1	Decreased Sensitivity of Carcinoembryonic Antigen cDNA-Transfected Cells to Adriamycin, Hitoshi Kawaharata, Yuji Hinoda, Fumio Itoh, Takao Endo, Shinzo Oikawa, Hiroshi Nakazato, and Kobzoh Imai, Int. J. Cancer, Vol. 72, pp. 377-382, 1997.
AM	1	Two COOH-Terminal Truncated Cytoplasmic Forms of Topoisomerase II in a VP-16-Selected Lung Cancer Cell Line Results from Partial Gene Deletion and Alternative Splicing, Qiang Yu, Shelagh E. L. Mirski, Kathryn E. Sparks, and Susan P. C. Cole, Biochemistry, Vol. 36, pp. 5868-5877, 1997.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO 1 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO.		APPLICATION NO.
	10460-7 (53836-5001)		Not Yet Assigned
	APPLICANT(S)		
	Rbss et al. 028754-039		
FILING DATE		GROUP	
Herewith		1646	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1						Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>1</u>	H19 Gene Overexpression in Atypical Multidrug-resistant Cells Associated with Expression of a 95-Kilodalton Membrane Glycoprotein, L. Austin, Weidong Yang, Arung, Arun K. Rishi, Yongming Gao, and Douglas D. Ross, Cancer Research 56, 2904-2904, July 1, 1996.
	AS	<u>1</u>	A multidrug resistance transporter form human MCF-7 breast cancer cells, L. Austin Doyle, Weidong Yang, Lynne V. Abruzzo, Tammy Krogmann, Yongming Gao, Arun K. Rishi, and Douglas D. Ross. Proc. Natl. Acad. Sci. USA, Vol 95, pp. 15665-15670, December 1998, Medical Sciences.
	AT	<u>1</u>	A Human Placenta-Specific ATP-Binding Cassette Gene (ABCP) on Chromosome 4q22 That Is Involved in Multidrug Resistance. Rando Allikmets, Lynn M. Schriml, Amy Hutchinson, Vincenzo Ramano-Spica, and Michael Dean, Cancer 5337-5339, December 1, 1998.
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTQ 1 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO.	APPLICATION NO.
	10460-7 (53836-5001)	Not Yet Assigned
	APPLICANT(S)	
	Ross et al.	028754-039
FILING DATE		GROUP
Herewith		1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1						Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	1	Molecular Cloning of cDNAs Which Are Highly Overexpressed in Mitoxantrone resistant Cells: Demonstration of Homology to ABC Transport Genes. Keisuke Miyake, Lyn Mickley, Tomas Litman, Zhirong Zhan, Robert Robey, Barbara Cristensen, Marifiorella Brangi, Lee Green Berger, Michael Dean, Tito Fojo, and Susan E. Bates, Cancer Research 59, 8-13, January 1, 1999.
	AS	1	A Human Canalicular Multispecific Organic Anion Transporter (cMOAT) Gene Is Overexpressed in Cisplatin-resistant Human Cancer Cell Lines with Decreased Drug Accumulation. Ken Taniguchi, Morimase Wada, Kimitoshi Kohno, Takanori Nakamura, Takeshi Kawabe, Mina Kawakami, Kazuhiro Kagotani, Katsuzumi Okumura, Shin-ichi Akiyama, and Michihiko Kuano, Cancer Research 56 4124-4129, September 15, 1996.
	AT	1	Cloning of the cDNA for a Human Homologous to 21q22.3 of the Drosophila White Gene and Mapping to Chromosome 21q22.3. Haiming Chen, Colette Rossier, Maria D. Lalioti, Audrey, Lynn, Aravinda Chakravarti, Caelle Perrin, and Stylianos E. Antonarakis, Am. J. Genet. 59:66-75, 1996
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			